

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 6B




Fig. 7

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY FOLATE HYDROLASE ACTIVITY PRESENT IN 0.0002 ug rSPSMA #7




Fig. 8

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY
FOLATE HYDROLASE ACTIVITY PRESENT IN 0.0002 ug rsPSMA #8




Fig. 9

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu₂ BY FOLATE HYDROLASE ACTIVITY PRESENT IN C4-2 CELL MEMBRANE PREP, 8/15/01




Fig. 10




Fig. 11




Fig. 12

Human IgG1 cloning – into pcDNA

Construction of pcDNA-huCκ and pcDNA-huIgG1

		PCR product	Vector
Cκ	Sense	5' XbaI HindIII BamHI NheI 3'	5' NheI NotI 3'
	Anti-sense	EcoRI NotI	(pcDNA.neo)
Cγ1	Sense	5' XbaI KpnI HindIII BamHI NheI 3'	5' NheI/PmeI 3'
	Anti-sense	EcoRI XhoI PmeI	(pcDNA Hygro)

Construction of pcDNA-Ab (V-C cassette)

		PCR product	Vector
Vκ	Sense	BglII or BamHI (if necessary)*	5' BamHI NheI 3'
	Anti-sense	NheI	(pcDNA-huCκ)
Vγ1	Sense	BglII or BamHI (if necessary)*	5' BamHI NheI 3'
	Anti-sense	XbaI	(pcDNA-huIgG1)

* BamHI primer is used if the V region has an internal BglII site

Human IgG cloning – V-C cassette from pcDNA into "production" vector

	Insert from pcDNA
Igκ	5' HindIII or BamHI (if alternate sense primer used) 3' EcoRI, NotI, XhoI, XbaI or PmeI
IgG1	5' KpnI, HindIII or BamHI (if alternate sense primer used) 3' EcoRI*, XhoI or PmeI

* 2nd EcoRI site present in hygromycin resistance gene

Primers used for V region amplification

Vκ-sense:

5' GAAGATCTCACC ATG + 20-23 bp leader sequence 3'
BglII Kozak

Vκ anti-sense (reverse/complementary):

5' AACTA GCT AGC AGT TCC AGA TTT CAA CTG CTC ATC AGA T 3'
S A T G S K L Q E D S (aa. 23-13 Cκ)
NheI

Cloning site of NheI codes for A S - therefore no amino acid change due to cloning.

Vγ-sense:

5' GAAGATCTCACC ATG + 17-29bp leader sequence 3'
BglII Kozak

Vγ anti-sense(reverse/complementary):

5' GC TCT AGA GGG TGC CAG GGG GAA GAC CGA T 3'
(R) S P A L P F V S (aa. 14-7 Cγ1)
XbaI

Cloning into

5' CG GCT AGC
S (A)

Cloning site junction of XbaI/NheI (TCT AGC) codes for S S - therefore no amino acid change due to cloning.

Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25




Fig. 26




Fig. 27

Anti-PSMA mAbs bind specifically to cell surface PSMA




Fig. 28A

Anti-PSMA mAb binding to cell surface PSMA **(Unpurified mAb in culture supernatant)**




Fig. 28B

Purified anti-PSMA Abs binding to cell surface PSMA




Fig. 28C






Fig. 29






Fig. 30




Fig. 3 \

Competition




Fig. 32




Fig. 33




Fig. 34




Fig. 35




Fig. 36




Fig. 37





Fig. 38

C4-2



LNCaP




Fig. 39




Fig. 40





Fig. 41

Radio-HPLC profile Cell Based Immunoreactivity (%)



mAb	PSMA	3T3
006	85.8	1.0
026	83.4	1.4
mJ591	46.2	1.7
IgG	5.9	0.7

Fig. 42





Fig. 43





Fig. 44

Fig. 45



¹⁷⁷Lu Labeled mAb 026




Fig. 46




Fig. 47




Fig. 48




Fig. 49




Fig. 50

FLOW CYTOMETRY DATA















TREATMENT GROUP	RESULTS									
LOT # 4019-C001										
CONTROLS										

Fig. 51




Fig. 52




Fig. 53